
United States · Information services startup
MMIT (Managed Markets Insight & Technology, LLC) is a prominent provider of market access data, analytics, and advisory services in the pharmaceutical, healthcare, and payer sectors.
Funding reportedLast round: Venture (Round not Specified)
Follow MMIT and see its new rounds in your feed. Start following
MMIT (Managed Markets Insight & Technology, LLC) is a prominent provider of market access data, analytics, and advisory services in the pharmaceutical, healthcare, and payer sectors.
Based in Yardley, Pennsylvania, with additional offices across the U.S., MMIT focuses on clarifying drug coverage and improving patient access to lifesaving treatments. As part of Norstella, the company serves over 1,300 biopharma and payer clients, offering insights into pharmacy and medical benefit information. MMIT specializes in market access data, providing comprehensive information on formularies, medical policies, and restrictions. Their expert teams analyze market trends and reimbursement policies to deliver actionable insights. The company also offers advisory solutions to help pharmaceutical manufacturers and payers navigate complex healthcare markets, ensuring a smooth patient journey from diagnosis to treatment. With a commitment to transparency, MMIT's products illuminate paths to better patient access through data-driven solutions.
Funding, as reported
What they build
Known for
patient engagement strategieshealth caremanagement consultingmarket accessmarket access strategyreal-world data integrationdrug coverage analyticshealthcare analyticscustomer engagementmarket access datarapid response servicespayer policy analysisunderstanding payer behaviormarket segmentationclinical notes analysisreal-world data
Built with from their website
accessiBeAzure DevopsPendo.Google Tag ManagerDriftTableauWordPress.orgAtlassianDNS Made EasyTwitter Analytics
Linkedin Insight TagFont AwesomeElementorCloudFlareViewport MetaLinkedIn AdsAtlassian CloudMimecast
Add your raise, your deck and your story, and put MMIT in front of investors. Or tell us what we have wrong.